Lymphoma News

SAN DIEGO — Patients with lymphoma who receive palliative care incur significantly lower total hospitalization charges than patients who do not, according to study findings presented at ASH Annual Meeting and Exposition.

Social determinants of health for children and young adults with leukemia and lymphoma must be researched as much as the diseases themselves to improve care, according to a presenter at ASH Annual Meeting and Exposition.

Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.

Chimeric antigen receptor T cells have improved survival rates as second-line therapy for individuals with high-risk diffuse large B-cell lymphoma, but available therapies lack cost-effectiveness at current prices, study results showed.

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

For individuals diagnosed with cancer, guideline-concordant exercise reduced all-cause mortality by 25% compared with patients with cancer who did not exercise, study results published in Journal of Clinical Oncology showed.

The FDA published a safety advisory on the risk of T-cell malignancies among individuals receiving autologous chimeric antigen receptor T-cell therapy for the treatment of certain blood cancers.

Three physicians have been elected to serve in leadership roles on ASH’s executive committee.

Precision oncology therapies requiring biomarker testing comprised 43% of all FDA oncology drug approvals between 1998 and 2022, study results published in Cancer Discovery showed.

The FDA announced several regulatory actions.